L E Heasley
Overview
Explore the profile of L E Heasley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandulache V, Lei Y, Heasley L, Chang M, Amos C, Sturgis E, et al.
Oral Oncol
. 2019 Oct;
102:104440.
PMID: 31648864
No abstract available.
2.
Ohm A, Tan A, Heasley L, Reyland M
Oncogene
. 2017 Apr;
36(30):4370-4378.
PMID: 28368426
Recent studies suggest that the presence of a KRAS mutation may be insufficient for defining a clinically homogenous molecular group, as many KRAS mutant tumors lose reliance on K-Ras for...
3.
Nakachi I, Helfrich B, Spillman M, Mickler E, Olson C, Rice J, et al.
Clin Transl Sci
. 2016 Oct;
9(6):293-301.
PMID: 27766744
Src kinase is recognized as a key target for molecular cancer therapy. However, methods to efficiently select patients responsive to Src inhibitors are lacking. We explored the sensitivity of ovarian...
4.
Ware K, Hinz T, Kleczko E, Singleton K, Marek L, Helfrich B, et al.
Oncogenesis
. 2013 Apr;
2:e39.
PMID: 23552882
Despite initial and often dramatic responses of epidermal growth factor receptor (EGFR)-addicted lung tumors to the EGFR-specific tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, nearly all develop resistance and relapse....
5.
Linger R, Cohen R, Cummings C, Sather S, Migdall-Wilson J, Middleton D, et al.
Oncogene
. 2012 Aug;
32(29):3420-31.
PMID: 22890323
Non-small cell lung cancer (NSCLC) is a prevalent and devastating disease that claims more lives than breast, prostate, colon and pancreatic cancers combined. Current research suggests that standard chemotherapy regimens...
6.
Kono S, Heasley L, Doebele R, Camidge D
Curr Cancer Drug Targets
. 2011 Dec;
12(2):107-23.
PMID: 22165970
The treatment of advanced non � small cell lung cancer (NSCLC) increasingly involves the use of molecularly targeted therapy with activity against either the tumor directly, or indirectly, through activity...
7.
Heasley L
Oncogene
. 2001 Apr;
20(13):1563-9.
PMID: 11313903
Autocrine and paracrine signaling leading to stimulation of tumor cell growth is a common theme in human cancers. In addition to polypeptide growth factors such as EGF family members which...
8.
Dreskin S, Thomas G, Dale S, Heasley L
J Immunol
. 2001 Apr;
166(9):5646-53.
PMID: 11313405
Ten isoforms of c-jun N-terminal kinase (JNK) have been described that arise by differential mRNA splicing of three genes. In that the relative expression and function of these different JNK...
9.
Pugazhenthi S, Nesterova A, Sable C, Heidenreich K, Boxer L, Heasley L, et al.
J Biol Chem
. 2001 Feb;
275(15):10761-6.
PMID: 10753867
In our previous study we showed that insulin-like growth factor-I induces a cAMP-response element (CRE) site-containing Bcl-2 promoter through a novel signaling pathway involving mitogen-activated protein kinase kinase 6/p38beta mitogen-activated...
10.
Levresse V, Butterfield L, Zentrich E, Heasley L
J Neurosci Res
. 2000 Dec;
62(6):799-808.
PMID: 11107164
The protein serine/threonine kinase Akt is a target of phosphatidylinositol 3-kinase that mediates many of the trophic actions of growth factors on cells. In PC12 cells, complete removal of serum...